{"id":"W4392387942","doi":"10.3389/fonc.2023.1343027","title":"Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms","year":2024,"lang":"en","type":"erratum","venue":"Frontiers in Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University","funders":"","keywords":"Lenvatinib; Sunitinib; Pembrolizumab; Renal cell carcinoma; Medicine; Oncology; Internal medicine; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005614548,0.002099091,0.00281806,0.0024047,0.001629756,0.003742827,0.003239308,0.006482159,0.04447668],"category_scores_gemma":[0.04065235,0.0009986602,0.003842338,0.001851342,0.001114586,0.001651139,0.001198977,0.009121619,0.01738202],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004385717,"about_ca_system_score_gemma":0.006777598,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02186699,"about_ca_topic_score_gemma":0.04478217,"domain_scores_codex":[0.9968069,0.0006757779,0.000463319,0.0004085738,0.001285672,0.0003597744],"domain_scores_gemma":[0.9828544,0.004844639,0.0009946537,0.0006788145,0.009155292,0.001472209],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006084261,0.000007375324,0.00006530908,0.0001225971,0.0000309102,0.00005061613,0.000004868046,0.00002179698,0.00001539951,0.000116566,0.9962314,0.003272336],"study_design_scores_gemma":[0.0007571373,0.0001257641,0.002880215,0.001291005,0.000562917,0.0005422337,0.00005235968,0.0004659419,0.0003511251,0.00171401,0.991165,0.00009236698],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.0001379207,0.003105658,0.0003903415,0.08212183,0.9085669,0.00007721664,0.003143088,0.0002558968,0.002201263],"genre_scores_gemma":[0.006306851,0.01166192,0.003073417,0.2705267,0.5979105,0.0005862619,0.007793702,0.0008142426,0.1013264],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.04447668,"threshold_uncertainty_score":0.1487893,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02340401623441505,"score_gpt":0.2998702179532843,"score_spread":0.2764662017188692,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}